Company profile
Altimmune, Inc.
NASDAQ:ALTBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ALT-801 | phase2 | — | 5 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (19)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04561245 | phase1 | completed | 2020-11-10 | 2021-10-29 | Altimmune, Inc. | ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability |
| NCT05006885 | phase1 | completed | 2021-09-30 | 2022-08-17 | Altimmune, Inc. | ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) |
| NCT05134662 | phase1 | completed | 2022-02-01 | 2023-02-03 | Altimmune, Inc. | ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM) |
| NCT05295875 | phase2 | completed | 2022-03-31 | 2023-09-28 | Altimmune, Inc. | Efficacy and Safety of ALT-801 in the Treatment of Obesity |
| NCT05292911 | phase1 | completed | 2022-03-09 | 2022-10-31 | Altimmune, Inc. | Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD) |
FDA applications (0)
No records yet.